

14 March 2017

Dr Swee T Tan  
Gillies McIndoe Research Institute  
PO Box 7184  
Newtown  
Wellington 6242

Dear Dr Tan

Re:	<b>Ethics ref:</b>	<b>17/CEN/8</b>
	Study title:	Treatment of Patients with Advanced Cancer by Targeting Cancer Stem Cells Using Modulators of the Renin-Angiotensin System

I am pleased to advise that this application has been approved by the Central Health and Disability Ethics Committee. This decision was made through the HDEC-Full Review pathway.

#### Conditions of HDEC approval

HDEC approval for this study is subject to the following conditions being met prior to the commencement of the study in New Zealand. It is your responsibility, and that of the study's sponsor, to ensure that these conditions are met. No further review by the Central Health and Disability Ethics Committee is required.

Standard conditions:

1. Before the study commences at *any* locality in New Zealand, all relevant regulatory approvals must be obtained.
2. Before the study commences at *any* locality in New Zealand, it must be registered in a clinical trials registry. This should be a WHO-approved (such as the Australia New Zealand Clinical Trials Registry, [www.anzctr.org.au](http://www.anzctr.org.au)). However <https://clinicaltrials.gov/> is acceptable provided registration occurs prior to the study commencing at *any* locality in New Zealand.
3. Before the study commences at a *given* locality in New Zealand, it must be authorised by that locality in Online Forms. Locality authorisation confirms that the locality is suitable for the safe and effective conduct of the study, and that local research governance issues have been addressed.

#### After HDEC review

Please refer to the *Standard Operating Procedures for Health and Disability Ethics Committees* (available on [www.ethics.health.govt.nz](http://www.ethics.health.govt.nz)) for HDEC requirements relating to amendments and other post-approval processes.

Your next progress report is due by 14 March 2018.

Participant access to ACC

The Central Health and Disability Ethics Committee is satisfied that your study is not a clinical trial that is to be conducted principally for the benefit of the manufacturer or distributor of the medicine or item being trialled. Participants injured as a result of treatment received as part of your study may therefore be eligible for publicly-funded compensation through the Accident Compensation Corporation (ACC).

Please don't hesitate to contact the HDEC secretariat for further information. We wish you all the best for your study.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Helen Walker', written in a cursive style.

Mrs Helen Walker  
Chairperson  
Central Health and Disability Ethics Committee

Encl: appendix A: documents submitted  
appendix B: statement of compliance and list of members

**Appendix A**  
**Documents submitted**

<i>Document</i>	<i>Version</i>	<i>Date</i>
Consent form for Photographic and Radiographic material.	1	15 November 2016
Study plan	V1	16 November 2016
Evidence of scientific review: Scientific review	V1	16 November 2016
Protocol: Clinical study protocol	V.1	10 January 2017
CV for CI: C.V	V.3	11 January 2017
PIS/CF: Patient information sheet and consent form for cancer study	V.1	11 January 2017
PIS/CF: Patient information and consent sheet for future study.	V.1	11 January 2017
Application	1	-
PIS/CF: Patient information and consent forms	V.2	06 March 2017
PIS/CF: Patient information and consent for future study	V.2	06 March 2017
Response to Request for Further Information	1	-

## Appendix B Statement of compliance and list of members

### Statement of compliance

The Central Health and Disability Ethics Committee:

- is constituted in accordance with its Terms of Reference
- operates in accordance with the *Standard Operating Procedures for Health and Disability Ethics Committees*, and with the principles of international good clinical practice (GCP)
- is approved by the Health Research Council of New Zealand's Ethics Committee for the purposes of section 25(1)(c) of the Health Research Council Act 1990
- is registered (number 00008712) with the US Department of Health and Human Services' Office for Human Research Protection (OHRP).

### List of members

<i>Name</i>	<i>Category</i>	<i>Appointed</i>	<i>Term Expires</i>
Mrs Helen Walker	Lay (consumer/community perspectives)	01/07/2015	01/07/2018
Dr Angela Ballantyne	Lay (ethical/moral reasoning)	30/07/2015	30/07/2018
Dr Melissa Cragg	Non-lay (observational studies)	30/07/2015	30/07/2018
Dr Peter Gallagher	Non-lay (health/disability service provision)	30/07/2015	30/07/2018
Mrs Sandy Gill	Lay (consumer/community perspectives)	30/07/2015	30/07/2018
Dr Ptries Herst	Non-lay (intervention studies)	27/10/2015	27/10/2018
Dr Dean Quinn	Non-lay (intervention studies)	27/10/2015	27/10/2018
Dr Cordelia Thomas	Lay (ethical/moral reasoning)	19/05/2014	19/05/2017

Unless members resign, vacate or are removed from their office, every member of HDEC shall continue in office until their successor comes into office (HDEC Terms of Reference)

<http://www.ethics.health.govt.nz>